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Abstract
Background: Cardiovascular disease (CVD) is the leading cause of death globally. Community pharmacist
intervention studies have demonstrated clinical effectiveness for improving several leading individual CVD risk
factors. Primary prevention strategies increasingly emphasise the need for consideration of overall cardiovascular
risk and concurrent management of multiple risk factors. It is therefore important to demonstrate the feasibility of
multiple risk factor management by community pharmacists to ensure continued currency of their role.
Methods/Design: This study will be a longitudinal pre- and post-test pilot study with a single cohort of up to 100
patients in ten pharmacies. Patients aged 50-74 years with no history of heart disease or diabetes, and taking
antihypertensive or lipid-lowering medicines, will be approached for participation. Assessment of cardiovascular risk,
medicines use and health behaviours will be undertaken by a research assistant at baseline and following the
intervention (6 months). Validated interview scales will be used where available. Baseline data will be used by
accredited medicines management pharmacists to generate a report for the treating community pharmacist. This
report will highlight individual patients’ overall CVD risk and individual risk factors, as well as identifying modifiable
health behaviours for risk improvement and suggesting treatment and behavioural goals. The treating community
pharmacist will use this information to finalise and implement a treatment plan in conjunction with the patient
and their doctor. Community pharmacists will facilitate patient improvements in lifestyle, medicines adherence, and
medicines management over the course of five counselling sessions with monthly intervals. The primary outcome
will be the change to average overall cardiovascular risk, assessed using the Framingham risk equation.
Discussion: This study will assess the feasibility of implementing holistic primary CVD prevention programs into
community pharmacy, one of the most accessible health services in most developed countries.
Trial registration: Australia and New Zealand Clinical Trial Registry Number: ACTRN12609000677202
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Cardiovascular disease (CVD) is the leading cause of
death globally, accounting for an estimated 17.1 million
deaths per annum - 29% of all deaths [1]. The relative
contribution of CVD to the burden of disease remains
high in countries with low-, middle-, and high incomes
[1]. Despite significant gaps in research, there is suffi-
cient evidence (particularly from developed nations such
as the United States and United Kingdom) to suggest
that the primary prevention of CVD represents a cost
effective approach to reducing this burden [2].
There is a cluster of highly prevalent CVD risk factors
in many developing and most developed countries
including Australia which can be controlled or avoided:
tobacco smoking, hypertension, overweight and obesity,
physical inactivity, dyslipidaemia (high cholesterol), poor
nutrition and diabetes [1,3]. Significant evidence-treat-
ment gaps remain in the management of each of these,
culminating in substantially elevated incidences of CVD
in most countries. Community pharmacists are highly
accessible health professionals in most communities and
have demonstrated an effective role in the management
of several of these risk factors [4-7]. Guidelines on pri-
mary CVD prevention now highlight the importance of
overall CVD risk assessment rather than traditional indi-
vidual risk factor assessment, resulting in a much
greater emphasis on multiple risk factor management
[8-13].
The expertise of community pharmacists in medicines
management including adherence screening and man-
agement, and a growing role in health promotion has
resulted in several studies demonstrating effective phar-
macist involvement with multiple CVD risk factor man-
agement [14-16]. However, we are not aware of any
multiple risk factor study specifically examining struc-
tured, pharmacist-led disease state management pro-
grams for primary CVD prevention in a non-diabetic
population. The Pharmacist Assessment of Adherence,
Risk and Treatment in Cardiovascular Disease (PAART
CVD) was developed as a pilot project to address this
evidence gap.
This paper describes the research protocol developed
for the PAART CVD project, a community-pharmacy
based CVD primary prevention pilot project in a non-
diabetic, adult population. We also identify the theoreti-
cal framework, local issues affecting implementation
decisions, and gaps in current knowledge experienced to
facilitate future adaptation.
Goals of research
1. To assess the feasibility of implementing a pri-
mary CVD prevention program in a community
pharmacy setting
2. To measure changes to cardiovascular health for
patients receiving the PAART CVD intervention.
Methods and Design
Study design and setting
This is a longitudinal pre- and post-test study to be
undertaken with a single cohort of patients. Ten phar-
macies from two States (Victoria and Tasmania) will be
recruited - five each from rural and metropolitan loca-
tions. Each pharmacy will be asked to approach a conve-
nience sample of patients meeting the inclusion criteria,
with a goal of recruiting 10 participants per pharmacy.
Local general practices and general practice organisa-
tions will be informed about the project.
Outcomes examined
T h ep r i m a r yo u t c o m ef o rt h ei n t e r v e n t i o nw i l lb et h e
average change to estimated 5-year risk of primary onset
of CVD between baseline and six months calculated
using the New Zealand CVD risk scores [11], a modified
version of the Framingham-based risk equation [17].
Secondary health outcomes include change to blood
pressure, lipid profile, random blood glucose, waist,
body mass index (BMI), and depression score.
Pharmacist training
Over two consecutive days, pharmacists from recruited
pharmacies will attend training focussed on the follow-
ing key topics:
￿ health promotion and behavioural change
￿ overall CVD risk and CVD risk assessment
￿ medicines adherence
￿ medicines management for cardiovascular risk
factors
￿ lifestyle modification (diet, physical activity, weight
management, alcohol consumption)
￿ antiplatelet use for primary CVD prevention
￿ smoking cessation
￿ managing patients who screen positively for dia-
betes, alcohol abuse or depression; and
￿ General Practitioner (GP) and other health profes-
sional engagement.
All training, including training materials, will be con-
sistent with relevant national guidelines and will be tai-
lored to suit a generalist community pharmacist
audience. Emphasis will be placed on the need for phar-
macists to act within their professional competencies
and take appropriate action if situations arise outside
their competencies (e.g. patient screens positive for
depression). Written guidelines will be provided to
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that warrant referral to a GP or another health profes-
sional (e.g. dietitian). Pharmacists will also be advised on
options for referral (e.g. how to access specialist dietary
or smoking cessation advice) when they might deem it
appropriate.
Subject eligibility criteria
Inclusion criteria
To be eligible for participation in the study, patients
need to be
￿ aged 50-74 years
￿ currently taking one or more medicines for choles-
terol and/or hypertension, and
￿ free from established cardiovascular disease, dia-
betes or a cardiovascular event.
Individuals will be excluded from the study in the fol-
lowing instances:
￿ patients with a complex debilitating coexisting
medical condition
￿ target organ damage
￿ any cognitive impairment
￿ reliance on a carer or living in a residential aged
care facility
￿ recent hospital inpatients who were medical admis-
sions and discharged less than four weeks prior to
recruitment
￿ non-English speaking
￿ living more than 40 km from a participating
pharmacy
￿ patients who have received a Home Medicines
Review (HMR) in the past 12 months
￿ deemed inappropriate for the intervention by the
patient’s GP; or
￿ patients of GPs who express a desire not to have
any involvement with this project.
Patient recruitment
Pharmacists will initially be asked to conduct a simple
pre-screening of potential participants based on the
inclusion criteria outlined above. The information
required (CVD history, use of CVD medicines, and age)
is quick and easy to obtain from dispensing records and
patient interview. Potential participants expressing inter-
est will be provided with written patient information
and an Expression Of Interest (EOI) form to be com-
pleted and returned to researchers.
Upon receipt of EOIs or direct patient-initiated con-
tact via a free telephone number, a formal assessment of
all eligibility requirements will be undertaken by
researchers and a provisional baseline assessment date
agreed. If eligible, consent must be obtained to contact
their GP in writing and to provide the GP with an
opportunity to comment on the appropriateness of par-
ticipation. Written consent for participation and sharing
of health information with relevant health professionals
is to be provided by patients prior to baseline
assessment.
Patient data collection
Baseline and final (6 month) patient information will be
collected by trained research assistants (RAs). This process
will take 60-90 minutes on both occasions and can take
place in the patient’s home (preferred), or in a private area
at the pharmacy or their workplace. Assessment involves
anthropometric and Point Of Care (POC) biomedical test-
ing, and an administered questionnaire using validated
scales where possible. Lipid profiles and fasting blood glu-
cose levels will be obtained using Cholestech LDX® Analy-
zers [18,19], in accordance with instructions provided by
the manufacturer. This device uses finger-prick testing
and provides results within 10 minutes. Quality control
samples will be used to validate the machine prior to mea-
surements. Patients will be advised that the most accurate
results for cholesterol and blood glucose levels would be
obtained by fasting 12-16 hours prior to the initial assess-
ment interview and testing, and to take their medications
as normal on the day of clinical assessment. Fasting time
will be recorded to aid clinical interpretation.
When the patient is rested, blood pressure (BP) will be
measured using an Omron 1A1B® automated BP moni-
tor in accordance with WHO MONICA Monitoring of
Trends and Determinants of Cardiovascular Diseases
and the European Health Risk Monitoring protocols
[20,21] amended for use with an automated monitor.
The average of two measurements taken 2-3 minutes
apart will be used, but if systolic BP measurements differ
by 10 mmHg or greater, or diastolic BP differ by 6
mmHg or greater, a third reading will be taken. In this
instance the average of the two closest systolic and two
closest diastolic BP measurements will be used to define
the BP. The RA will advise patients to seek immediate
medical attention if systolic BP is 180 mmHg or greater,
or if diastolic BP is 110 mmHg or greater. Weight,
height, and waist and hip circumferences will be mea-
sured in accordance with the EHRM protocol [21].
The remainder of the assessment will consist of a
researcher-administered questionnaire (all interviewing
researchers have pharmacy qualifications). This ques-
tionnaire, which includes several validated survey instru-
ments, covers a range of health indicators:
￿ demographic and social information, including
some questions based on the WHO MONICA
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[21], as adapted for the Greater Green Triangle
Chronic Disease Risk Factor Studies [22]
￿ brief patient medical history and family history of
CVD events
￿ details of current medicines
￿ details of recent testing for CVD risk factors prior
to baseline
￿ adherence to current medications advice using the
Tool for Adherence Behaviour Screening (TABS)
[23] and the Morisky scale [24]
￿ smoking, physical activity and weight management
status - including some screening questions from the
‘Lifescripts’ program [25] and questions from surveys
used by the Greater Green Triangle Chronic Disease
Risk Factor Studies [22]
￿ nutrition and adherence to national dietary guide-
lines, based on Dietary Guidelines for Australian
Adults (2003) [26] and using a number of questions
from the National Nutrition Survey 1995 [27], and
the Cancer Council of Victoria Food Frequency
Questionnaire [28]
￿ screening for excess alcohol consumption using the
AUDIT C tool [29]
￿ screening for depression using the Center for Epi-
demiological Study of Depression Scale (CES-D) [30]
￿ quality of life measure using the SF-12v2 Health
Survey™ (Ware et al, 2007) [31].
Pharmacists will be asked to supply medicines dispen-
sing data for the six months’ period prior to baseline
data collection and the six months prior to follow up
data collection. To account for medicines collected else-
where, patients will be asked during their interviews to
recall any quantities of medicines obtained elsewhere for
the specified period.
Intervention part one: accredited pharmacist review
Using relevant national clinical guidelines as the bench-
mark for management, pharmacists accredited to under-
take collaborative, structured medicines management
reviews in community settings (known as ‘Home Medi-
cines Reviews’) will produce a written report for each
patient highlighting the estimated 5-year CVD risk, sub-
optimal CVD risk factors, and medication adherence
and other medicines use issues (see additional file 1 for
template). The report will also suggest patient treatment
goals and opportunities for beneficial lifestyle changes
and improved medicines management to achieve goals.
This report will be provided to the patient’s community
pharmacist with summaries for the patient and their
general practitioner.
Intervention part two: community pharmacist facilitating
patient change
Community pharmacists will be trained to deliver their
interventions in accordance with the Health Action Pro-
cess Approach (HAPA) [32] to behaviour change over
five counselling sessions conducted at monthly intervals.
The emphasis in counselling progresses from change
motivation initially (via improved self-efficacy, belief in
the need for change and belief that change will generate
positive outcomes), through to change maintenance and
relapse prevention strategies. Written, achievable goals
will be encouraged.
The first session with the patient will prioritise basic
health education regarding individual CVD risk and the
benefits of potential treatments. It also establishes
acceptable goals for the treatment process through
patient consultation, and how these might be achieved.
Finally, the pharmacist will discuss with the patient any
specific medication changes identified in the baseline
report that are recommended to improve adherence to
CVD guidelines. Community pharmacists will not be
trained or asked to make interventions related specifi-
cally to diabetes or mental health issues, but will be
alerted to any suboptimal assessment results in these
areas and asked to discuss with the patient the potential
need for GP input. Such issues will also be identified in
the baseline assessment summary provided to the GP.
If a patient’s overall 5-year CVD risk score is 5% or
less (considered very low ris k )t h e yw i l lb ea d v i s e dt o
discuss with their pharmacist whether they are likely to
benefit from continuing with the intervention. The deci-
sion to continue will be left to the pharmacist and the
patient. Pharmacists will be expected to assess and
document patient motivation to undertake various med-
ication and lifestyle changes. Following discussion with
each patient, the pharmacist will then forward the clini-
cal summary to the patient’s GP with any additional
comments considered relevant.
Subsequent sessions will involve: ensuring necessary
changes to medicines have been made; monitoring of
medicines adherence especially for new medicines; link-
ing patients with local health and other services that
provide relevant patient support; initiating lifestyle
change and supporting maintenance and relapse preven-
tion. Throughout these sessions, patient progress
towards goals will be continually reassessed, as will be
the goals themselves. GP input to patient treatment
plans will also be invited.
Primary outcomes
The primary outcome for the PAART CVD intervention
is the average change to overall estimated 5-year risk of
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tion of the Framingham-based CVD risk score [11,17].
Secondary outcomes
Other outcomes examined include:
￿ Changes to individual modifiable CVD risk factors
(blood pressure, lipid profile, Body Mass Index, waist
circumference, smoking status, depression)
￿ changes in medicines adherence assessed using
Morisky [24] and TABS scales [23]; and
￿ changes in key health behaviours (physical activity,
diet, alcohol intake, weight management).
Additional outcomes to be assessed include stake-
holder satisfaction (GP, pharmacist, patient) and process
audit based on community pharmacist documentation
of counselling sessions.
Sample size
With 80 subjects this study would have a 90% power to
show an absolute reduction in risk of 1% based on a
standard deviation in the change of risk of 2.7% with a
two sided p-value of 0.05. To account for potential sub-
ject drop out and loss to follow-up of 20% we will aim
to recruit 100 subjects.
Statistical analysis
Univariate comparisons between groups will be con-
ducted using chi-square test for equal proportion (or
Fisher’s exact tests where numbers are small) and
reported as numbers and percentages. Continuous nor-
mally distributed variables will be compared using Stu-
dent’s t-tests and reported as means (standard error)
whilst non-parametric data will be compared using Wil-
coxon rank-sum tests and reported as medians (inter-
quartile range). Pairwise differences between pre and
post values will be calculated using paired t-tests for
normally distributed data and Wilcoxon sign rank tests
for non-normally distributed data. To account for the
large number of comparisons being made, we will
employ a reduced 2-sided p-value of 0.01 to indicate
clear statistical significance.
If any parameter from POC finger prick testing is
found to be outside the measurable range for the
machine, the value of the closest measurable limit will
be given to that patient.
Health behaviours will largely be measured using
existing scales associated with the survey instruments
incorporated into baseline and follow-up assessment.
For the dietary assessment, no validated tools are avail-
able for use in an Australian population so a study-spe-
cific tool has been devised. This tool is a 13-item
questionnaire addressing dietary quality in this study
population and using previously validated questions
from the National Nutrition Survey and Cancer Council
of Victoria Food Frequency Questionnaire relating to
the nutrients of concern for primary prevention of CVD
[27,28]. Responses for each item will be scored between
zero (least healthy response option) and 10 (healthiest
option) - consistent with the developing literature in
this area of nutrition research [33]. This scoring allows
for an overall diet score to be generated ranging from 0
to 130.
The general quality of dietary intake will be inter-
preted using the guidance provided in table 1.
This score allows a good estimate of the level of
adherence to key diet-related behaviours. Constituent
elements of the 13-item questionnaire also allowed
development of sub-scales for these areas of significant
influence on cardiovascular health:
￿ fruit and vegetable intake (soluble fibre and
antioxidants)
￿ saturated fat and total fat intake
￿ omega-3 fatty acid intake
￿ fibre intake (insoluble fibre); and
￿ salt intake.
The sub-scales enable community pharmacists to deli-
ver more tailored dietary advice to participants.
The study protocol was approved by Monash Univer-
sity Human Research Ethics Committee (HREC), Uni-
versity of Tasmania HREC, Flinders University Social
and Behavioural Research Ethics Committee and the
Australia and New Zealand Clinical Trials Registry
(Trial Number ACTRN12609000677202).
Discussion
The protocol and methods outlined above provide an
intervention framework for managing multiple CVD risk
factors in community pharmacy or other primary care
settings. There is considerable incentive to demonstrate
feasibility and effectiveness of such a service in commu-
nity pharmacy, given the caution with which expanded
roles for pharmacists in vascular care have been greeted
by some [34]. While there is evidence of pharmacists’
Table 1 Scoring mechanism used to assess overall quality
of dietary intake
Diet score using
nutrition tool
Interpretation
104-130 High level of compliance with CVD dietary
guidelines (80% or more)
78-103 Medium level of compliance with CVD dietary
guidelines (60-79%)
77 or less Low level of compliance with CVD dietary
guidelines (59% or less)
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deliver basic post-screening counselling with some clini-
cal benefits [35-37], evidence is lacking to demonstrate
the full potential of their comprehensive, ongoing man-
agement of multiple CVD risk factors. This has led to
concerns about fragmentation of care and lack of com-
munication of results with doctors [34].
The HAPA model underpinning the approach to
behavioural change was chosen because of its success in
lifestyle-oriented diabetes prevention programs addres-
sing similar risk factors for non-diabetic populations,
including an implementation study based in Australian
primary care [38,39]. Collection of process audit data is
important to see how well this approach is adhered to
by pharmacists. The emphasis on use of assessment
scales for medicines adherence and various health beha-
viours is designed to promote ease of interpretation of
clinical assessments by community pharmacists who are
generalists in terms of their practice.
Several aspects of the protocol are context-specific
and their adoption by other researchers or health service
program managers may require consideration. Key
issues include:
￿ The restriction of eligibility to patients aged 50-74
years is in keeping with national guidelines advocat-
ing that screening of overall risk outside the 45-74
years age bracket is not economically viable [9]
￿ The use of accredited pharmacists has been
adopted to integrate with existing pharmacy skills
networks and remuneration systems, and to alleviate
time pressure for participating community pharma-
cists; there may be alternative workforce options to
produce clinical reports in different settings.
￿ Patients with established diabetes and CVD will be
excluded because there are existing evidence-based
models of care already in practice or at implementa-
tion stage; and
￿ Community pharmacy represents a key setting and
pharmacists are one of the most accessible health-
care providers in Australia, with expected competen-
cies in both medicines use and health promotion.
Limitations of study protocol
If the pilot testing indicates the feasibility of effective
community pharmacy interventions, it will be important
to validate this study with larger numbers and a control
group to comprehensively determine effectiveness, cost-
effectiveness and generalisability. Similarly, the six
month timeframe limits the ability to test the sustain-
ability of patient behaviour changes following the inter-
vention, and self-report - while often the only option -
for some health behaviours may be unreliable.
Validated dietary quality tools for cardiovascular
health are not available for the Australian population, so
we rely on a pilot with only face and content validity
developed by one of the authors (SOR). Current Austra-
lian guidelines for lipid disorders claim a lack of evi-
dence regarding appropriate cholesterol targets for
primary CVD prevention, thus restricting guidance for
practitioners. We relied on expert consensus developed
from examination of eligibility criteria for subsidised
lipid lowering medicines in Australia, previous guide-
lines, and values used for pathology lab reporting.
Conclusions
The proposed intervention integrates guideline evidence
and validated assessment tools where possible, but sev-
eral key knowledge gaps remain to preventing an
entirely evidence-informed approach. Protocols adopted
for other primary CVD prevention studies have not
been widely disseminated; hence this paper provides a
starting point for future research and implementation
programs in a primary care setting.
Additional material
Additional file 1: Clinical reporting form for baseline patient
information. This document is the template used by consultant
pharmacists to report baseline findings to pharmacists and doctors.
Forms are first provided to the community pharmacist to allow them to
add any comments before sending to the doctor. Examples of
comments about different aspects of patient health behaviours and
treatment are also provided.
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